We recently published 10 Big Names Crushing Wall Street. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the top-performing ...

BridgeBio Pharma (NASDAQ:BBIO) shares rose after it announced positive results from its late-stage study of BBP-418 on ...

The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after ...

BridgeBio Pharma will seek US approval of its limb-girdle muscular dystrophy (LGMD) small molecule after the drug met its ...

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...

BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

BridgeBio Pharma Inc.’s drug to treat a devastating muscle-wasting disorder met its goal in a late-stage trial, paving the ...

The search for a treatment for limb-girdle muscular dystrophy was started by the family of former Bank of America Corp. CEO ...

BridgeBio said an experimental therapy for a rare form of muscular dystrophy succeeded in a key trial, potentially setting up ...

Shares of BridgeBio Pharma rose after the company reported positive data in the phase three study of its treatment of limb-girdle muscular dystrophy. The stock rose 10% to $59.74 in premarket trading ...

To access the live webcast for BridgeBio's calls, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com . A replay of ...